BCL2 Is a Downstream Effector of MIZ-1 Essential for Blocking c-MYC-induced Apoptosis*

The c-MYC oncoprotein is among the most potent transforming agents in human cells. Ironically, c-MYC is also capable of inducing massive apoptosis under certain conditions. A clear understanding of the distinct pathways activated by c-MYC during apoptosis induction and transformation is crucial to the design of therapeutic strategies aimed at selectively reactivating the apoptotic potential of c-MYC in cancer cells. We recently demonstrated that apoptosis induction in primary human cells strictly requires that c-MYC bind and inactivate the transcription factor MIZ-1. This presumably blocked the ability of MIZ-1 to activate the transcription of an unidentified pro-survival gene. Here we report that MIZ-1 activates the transcription of BCL2. More importantly, inhibition of the MIZ-1/BCL2 signal is an essential event during the apoptotic response. Furthermore, targeting BCL2 with short hairpin RNA or small molecule inhibitors restores the apoptotic potential of a c-MYC mutant that is defective for MIZ-1 inhibition. These observations suggest that repression of BCL2 transcription is the single essential consequence of targeting the MIZ-1 pathway during apoptosis induction. These data define a genetic pathway that helps to explain historical observations documenting cooperation between c-MYC and BCL2 overexpression in human cancer.

[1]  S. McMahon,et al.  Targeting of Miz-1 Is Essential for Myc-mediated Apoptosis* , 2006, Journal of Biological Chemistry.

[2]  E. Wieschaus,et al.  Polycomb mediates Myc autorepression and its transcriptional control of many loci in Drosophila. , 2005, Genes & development.

[3]  Stephen W. Fesik,et al.  Promoting apoptosis as a strategy for cancer drug discovery , 2005, Nature Reviews Cancer.

[4]  S. McMahon,et al.  Metastasis-associated protein 1 (MTA1) is an essential downstream effector of the c-MYC oncoprotein. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[5]  C. Croce,et al.  miR-15 and miR-16 induce apoptosis by targeting BCL2. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[6]  S. Lowe,et al.  Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants , 2005, Nature.

[7]  R. Gascoyne,et al.  Amplification of IGH/MYC fusion in clinically aggressive IGH/BCL2‐positive germinal center B‐cell lymphomas , 2005, Genes, chromosomes & cancer.

[8]  Kathryn A. O’Donnell,et al.  c-Myc-regulated microRNAs modulate E2F1 expression , 2005, Nature.

[9]  S. Korsmeyer,et al.  An inhibitor of Bcl-2 family proteins induces regression of solid tumours , 2005, Nature.

[10]  S. Mukhopadhyay,et al.  Transformation of follicular lymphoma to Burkitt-like lymphoma within a single lymph node. , 2005, Human pathology.

[11]  M. Eilers,et al.  Pontin and Reptin regulate cell proliferation in early Xenopus embryos in collaboration with c-Myc and Miz-1 , 2005, Mechanisms of Development.

[12]  D. Matallanas,et al.  Myc Antagonizes Ras-mediated Growth Arrest in Leukemia Cells through the Inhibition of the Ras-ERK-p21Cip1 Pathway* , 2005, Journal of Biological Chemistry.

[13]  C. Barton,et al.  Transcriptional control of Nramp1: a paradigm for the repressive action of c-Myc. , 2004, Biochemical Society transactions.

[14]  S. Korsmeyer,et al.  Activation of Apoptosis in Vivo by a Hydrocarbon-Stapled BH3 Helix , 2004, Science.

[15]  S. Korsmeyer,et al.  Antiapoptotic BCL-2 is required for maintenance of a model leukemia. , 2004, Cancer cell.

[16]  A. Ozdek,et al.  C-Myc And Bcl-2 Expression In Supraglottic Squamous Cell Carcinoma of the Larynx , 2004, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[17]  S. McMahon,et al.  Analysis of genomic targets reveals complex functions of MYC , 2004, Nature Reviews Cancer.

[18]  E. Koonin,et al.  Regeneration of Peroxiredoxins by p53-Regulated Sestrins, Homologs of Bacterial AhpD , 2004, Science.

[19]  L. Penn,et al.  c-Myc represses the proximal promoters of GADD45a and GADD153 by a post-RNA polymerase II recruitment mechanism , 2004, Oncogene.

[20]  P. Bouillet,et al.  Bim is a suppressor of Myc-induced mouse B cell leukemia. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[21]  L. Kretzner,et al.  Autorepression of c-myc requires both initiator and E2F-binding site elements and cooperation with the p107 gene product , 2004, Oncogene.

[22]  R. Tjian,et al.  Myc-interacting protein 1 target gene profile: a link to microtubules, extracellular signal-regulated kinase, and cell growth. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[23]  John L Cleveland,et al.  Myc pathways provoking cell suicide and cancer , 2003, Oncogene.

[24]  J. Cleveland,et al.  c-Myc Augments Gamma Irradiation-Induced Apoptosis by Suppressing Bcl-XL , 2003, Molecular and Cellular Biology.

[25]  J. Cleveland,et al.  Puma is an essential mediator of p53-dependent and -independent apoptotic pathways. , 2003, Cancer cell.

[26]  F. Watt,et al.  Evidence that Myc activation depletes the epidermal stem cell compartment by modulating adhesive interactions with the local microenvironment , 2003, Development.

[27]  A. D. Buss,et al.  Identification of Chelerythrine as an Inhibitor of BclXL Function* , 2003, Journal of Biological Chemistry.

[28]  Andrea Cocito,et al.  Genomic targets of the human c-Myc protein. , 2003, Genes & development.

[29]  B. Lüscher,et al.  Stimulation of c‐MYC transcriptional activity and acetylation by recruitment of the cofactor CBP , 2003, EMBO reports.

[30]  S. Kim,et al.  Skp2 regulates Myc protein stability and activity. , 2003, Molecular cell.

[31]  M. Eilers,et al.  Myc represses differentiation-induced p21CIP1 expression via Miz-1-dependent interaction with the p21 core promoter , 2003, Oncogene.

[32]  Stella Pelengaris,et al.  c-MYC: more than just a matter of life and death , 2002, Nature Reviews Cancer.

[33]  John L Cleveland,et al.  c-Myc is essential for vasculogenesis and angiogenesis during development and tumor progression. , 2002, Genes & development.

[34]  S. Cory,et al.  The Bcl2 family: regulators of the cellular life-or-death switch , 2002, Nature Reviews Cancer.

[35]  M. Eilers,et al.  Negative regulation of the mammalian UV response by Myc through association with Miz-1. , 2002, Molecular cell.

[36]  A. Gartel,et al.  The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. , 2002, Molecular cancer therapeutics.

[37]  C. Albanese,et al.  E2F1 and c-Myc potentiate apoptosis through inhibition of NF-kappaB activity that facilitates MnSOD-mediated ROS elimination. , 2002, Molecular cell.

[38]  J. Cleveland,et al.  Bcl-2 is an apoptotic target suppressed by both c-Myc and E2F-1 , 2001, Oncogene.

[39]  H. Nakayama,et al.  A serine protease, HtrA2, is released from the mitochondria and interacts with XIAP, inducing cell death. , 2001, Molecular cell.

[40]  S. Korsmeyer,et al.  BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. , 2001, Molecular cell.

[41]  M. Roussel,et al.  Apoptosis Triggered by Myc-Induced Suppression of Bcl-XL or Bcl-2 Is Bypassed during Lymphomagenesis , 2001, Molecular and Cellular Biology.

[42]  R. Hehlmann,et al.  bcl‐2 expression in non‐Hodgkin's lymphomas is not associated with bcl‐2 gene rearrangements , 2001, British journal of haematology.

[43]  A. Strasser,et al.  BH3-Only Proteins—Essential Initiators of Apoptotic Cell Death , 2000, Cell.

[44]  N. Lee,et al.  Identification of c-myc responsive genes using rat cDNA microarray. , 2000, Cancer research.

[45]  E. Kandel,et al.  Induction of Cell Cycle Progression and Acceleration of Apoptosis Are Two Separable Functions of c-Myc: Transrepression Correlates with Acceleration of Apoptosis , 2000, Molecular and Cellular Biology.

[46]  Xiaodong Wang,et al.  Smac, a Mitochondrial Protein that Promotes Cytochrome c–Dependent Caspase Activation by Eliminating IAP Inhibition , 2000, Cell.

[47]  S. Srinivasula,et al.  Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[48]  E. Lander,et al.  Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[49]  U. Weidle,et al.  Control of cell growth by c-Myc in the absence of cell division , 1999, Current Biology.

[50]  G. Evan,et al.  c-Myc-induced sensitization to apoptosis is mediated through cytochrome c release. , 1999, Genes & development.

[51]  E. Prochownik,et al.  MYC oncogenes and human neoplastic disease , 1999, Oncogene.

[52]  D. Felsher,et al.  Transient excess of MYC activity can elicit genomic instability and tumorigenesis. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[53]  Ruedi Aebersold,et al.  Molecular characterization of mitochondrial apoptosis-inducing factor , 1999, Nature.

[54]  M. Cole,et al.  The Novel ATM-Related Protein TRRAP Is an Essential Cofactor for the c-Myc and E2F Oncoproteins , 1998, Cell.

[55]  J L Cleveland,et al.  Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. , 1998, Genes & development.

[56]  G. Carmichael,et al.  An alternative pathway for gene regulation by Myc , 1997, The EMBO journal.

[57]  L. M. Facchini,et al.  The Myc negative autoregulation mechanism requires Myc-Max association and involves the c-myc P2 minimal promoter , 1997, Molecular and cellular biology.

[58]  G. Cesareni,et al.  Analysis of the Myc and Max Interaction Specificity with λ Repressor-HLH Domain Fusions , 1995 .

[59]  W. Kaelin,et al.  Deregulated transcription factor E2F-1 expression leads to S-phase entry and p53-mediated apoptosis. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[60]  V. S. Prasad,et al.  Apoptosis and macrophage-mediated deletion of precursor B cells in the bone marrow of E mu-myc transgenic mice. , 1994, Blood.

[61]  A. Levine,et al.  p53 and E2F-1 cooperate to mediate apoptosis. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[62]  J. Trent,et al.  WAF1, a potential mediator of p53 tumor suppression , 1993, Cell.

[63]  S. Lowe,et al.  Stabilization of the p53 tumor suppressor is induced by adenovirus 5 E1A and accompanies apoptosis. , 1993, Genes & development.

[64]  N. Hay,et al.  Myc-mediated apoptosis is blocked by ectopic expression of Bcl-2 , 1993, Molecular and cellular biology.

[65]  G. Evan,et al.  Cooperative interaction between c-myc and bcl-2 proto-oncogenes , 1992, Nature.

[66]  S. Korsmeyer,et al.  The adenovirus E1A proteins induce apoptosis, which is inhibited by the E1B 19-kDa and Bcl-2 proteins. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[67]  D. Littman,et al.  Packaging system for rapid production of murine leukemia virus vectors with variable tropism , 1992, Journal of virology.

[68]  K. Kinzler,et al.  Definition of a consensus binding site for p53 , 1992, Nature Genetics.

[69]  J. Cleveland,et al.  Constitutive c-myc expression in an IL-3-dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis. , 1991, Oncogene.

[70]  T. McDonnell,et al.  Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14;18) , 1991, Nature.

[71]  G. Inghirami,et al.  Negative autoregulation of c‐myc gene expression is inactivated in transformed cells. , 1990, The EMBO journal.

[72]  A. Strasser,et al.  Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2 , 1990, Nature.

[73]  G. Evan,et al.  Domains of human c-myc protein required for autosuppression and cooperation with ras oncogenes are overlapping , 1990, Molecular and cellular biology.

[74]  L. Penn,et al.  Negative autoregulation of c‐myc transcription. , 1990, The EMBO journal.

[75]  S. Freytag.  Enforced expression of the c-myc oncogene inhibits cell differentiation by precluding entry into a distinct predifferentiation state in G0/G1 , 1988, Molecular and cellular biology.

[76]  M. Cole,et al.  Constitutive c-myc oncogene expression blocks mouse erythroleukaemia cell differentiation but not commitment , 1986, Nature.

[77]  R. Palmiter,et al.  The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice , 1985, Nature.

[78]  D. Boettiger,et al.  myc and src oncogenes have complementary effects on cell proliferation and expression of specific extracellular matrix components in definitive chondroblasts , 1985, Molecular and cellular biology.

[79]  H. Lachman,et al.  Expression of c-myc changes during differentiation of mouse erythroleukaemia cells , 1984, Nature.

[80]  T. Graf,et al.  Quail embryo fibroblasts transformed by four v‐myc‐containing virus isolates show enhanced proliferation but are non tumorigenic. , 1983, The EMBO journal.

[81]  P. Pelicci,et al.  "Myc represses transcription through recruitment of DNA methyltransferase corepressor" , 2005 .

[82]  K. Berns,et al.  Akt and 14-3-3η regulate Miz1 to control cell-cycle arrest after DNA damage , 2005, Nature Cell Biology.

[83]  John D. Watson,et al.  Promoter-binding and repression of PDGFRB by c-Myc are separable activities. , 2004, Nucleic acids research.

[84]  R. Berger,et al.  Presence of three recurrent chromosomal reaarrangements, t(2;3)(p12;q37), del(8)(q24), and t(14;18), in an acute lymphoblastic leukemia. , 1996, Cancer genetics and cytogenetics.

[85]  C. Dang,et al.  Max: functional domains and interaction with c-Myc. , 1992, Genes & development.

[86]  J. Cleveland,et al.  Negative regulation of c-myc transcription involves myc family proteins. , 1988, Oncogene research.

[87]  K. Maruyama,et al.  myc and E1A oncogenes alter the responses of PC12 cells to nerve growth factor and block differentiation. , 1987, Oncogene.